Literature DB >> 16891483

Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation.

Lucilla Baldassarri1, Roberta Creti, Simona Recchia, Monica Imperi, Bruna Facinelli, Eleonora Giovanetti, Marco Pataracchia, Giovanna Alfarone, Graziella Orefici.   

Abstract

Streptococcus pyogenes infections often fail to respond to antibiotic therapy, leading to persistent throat carriage and recurrent infections. Such failures cannot always be explained by the occurrence of antibiotic resistance determinants, and it has been suggested that S. pyogenes may enter epithelial cells to escape antibiotic treatment. We investigated 289 S. pyogenes strains isolated from different clinical sources to evaluate their ability to form biofilm as an alternative method to escape antibiotic treatment and host defenses. Up to 90% of S. pyogenes isolates, from both invasive and noninvasive infections, were able to form biofilm. Specific emm types, such as emm6, appeared to be more likely to produce biofilm, although variations within strains belonging to the same type might suggest biofilm formation to be a trait of individual strains rather than a general attribute of a serotype. Interestingly, erythromycin-susceptible isolates formed a significantly thicker biofilm than resistant isolates (P < 0.05). Among resistant strains, those carrying the erm class determinants formed a less organized biofilm than the mef(A)-positive strains. Also, prtF1 appeared to be negatively associated with the ability to form biofilm (P < 0.01). Preliminary data on a selection of strains indicated that biofilm-forming isolates entered epithelial cells with significantly lower efficiency than biofilm-negative strains. We suggest that prtF1-negative macrolide-susceptible or mef(A)-carrying isolates, which are poorly equipped to enter cells, may use biofilm to escape antimicrobial treatments and survive within the host. In this view, biofilm formation by S. pyogenes could be responsible for unexplained treatment failures and recurrences due to susceptible microorganisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891483      PMCID: PMC1594624          DOI: 10.1128/JCM.00512-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Relationship between asymptomatic carriage of Streptococcus pyogenes and the ability of the strains to adhere to and be internalised by cultured epithelial cells.

Authors:  Shlomo Sela; Revital Neeman; Nattan Keller; Asher Barzilai
Journal:  J Med Microbiol       Date:  2000-06       Impact factor: 2.472

2.  Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America.

Authors:  Alan L Bisno; Michael A Gerber; Jack M Gwaltney; Edward L Kaplan; Richard H Schwartz
Journal:  Clin Infect Dis       Date:  2002-07-15       Impact factor: 9.079

3.  Effects of environmental factors on streptococcal erythrogenic toxin A (SPE A) production by Streptococcus pyogenes.

Authors:  M S Chaussee; J Liu; D L Stevens; J J Ferretti
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

4.  Clinical and microbiological characteristics of severe group A streptococcal infections in Italy.

Authors:  C von Hunolstein; B Suligoi; M Pataracchia; F Scopetti; S Recchia; D Greco; G Orefici
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

Review 5.  Molecular basis of group A streptococcal virulence.

Authors:  A L Bisno; M O Brito; C M Collins
Journal:  Lancet Infect Dis       Date:  2003-04       Impact factor: 25.071

6.  Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices.

Authors:  G D Christensen; W A Simpson; J J Younger; L M Baddour; F F Barrett; D M Melton; E H Beachey
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

7.  Presence of the tet(O) gene in erythromycin- and tetracycline-resistant strains of Streptococcus pyogenes and linkage with either the mef(A) or the erm(A) gene.

Authors:  Eleonora Giovanetti; Andrea Brenciani; Remo Lupidi; Marilyn C Roberts; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Characterisation of group A streptococcal (GAS) isolates from children with tic disorders.

Authors:  R Creti; F Cardona; M Pataracchia; C Von Hunolstein; G Cundari; A Romano; G Orefici
Journal:  Indian J Med Res       Date:  2004-05       Impact factor: 2.375

9.  Protein F1 is required for efficient entry of Streptococcus pyogenes into epithelial cells.

Authors:  J Jadoun; V Ozeri; E Burstein; E Skutelsky; E Hanski; S Sela
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Streptococcus-zebrafish model of bacterial pathogenesis.

Authors:  Melody N Neely; John D Pfeifer; Michael Caparon
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  47 in total

1.  Environmental acidification drives S. pyogenes pilus expression and microcolony formation on epithelial cells in a FCT-dependent manner.

Authors:  Andrea G O Manetti; Thomas Köller; Marco Becherelli; Scilla Buccato; Bernd Kreikemeyer; Andreas Podbielski; Guido Grandi; Immaculada Margarit
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

2.  Response of Different Antibiotic Resistant Group of Streptococcus pyogenes to Environmental Stresses.

Authors:  Naser Abbas; Mahmoud Ismail; Mohamed El-Shahat Ebeid
Journal:  Indian J Microbiol       Date:  2012-05-15       Impact factor: 2.461

3.  Phosphotransferase System Uptake and Metabolism of the β-Glucoside Salicin Impact Group A Streptococcal Bloodstream Survival and Soft Tissue Infection.

Authors:  Rezia Era Braza; Aliyah B Silver; Ganesh S Sundar; Sarah E Davis; Afrooz Razi; Emrul Islam; Meaghan Hart; Jinyi Zhu; Yoann Le Breton; Kevin S McIver
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

4.  A Role of Epithelial Cells and Virulence Factors in Biofilm Formation by Streptococcus pyogenes In Vitro.

Authors:  Feiruz Alamiri; Yashuan Chao; Maria Baumgarten; Kristian Riesbeck; Anders P Hakansson
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

5.  Inhibition of Streptococcus pyogenes biofilm formation by coral-associated actinomycetes.

Authors:  Paramasivam Nithyanand; Ramalingam Thenmozhi; Janarthanam Rathna; Shunmugiah Karutha Pandian
Journal:  Curr Microbiol       Date:  2009-12-18       Impact factor: 2.188

6.  Superantigen SpeA attenuates the biofilm forming capacity of Streptococcus pyogenes.

Authors:  Anshu Babbar; Israel Barrantes; Dietmar H Pieper; Andreas Itzek
Journal:  J Microbiol       Date:  2019-06-27       Impact factor: 3.422

7.  Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.

Authors:  Tomas Fiedler; Catur Riani; Dirk Koczan; Kerstin Standar; Bernd Kreikemeyer; Andreas Podbielski
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

8.  Allelic replacement of the streptococcal cysteine protease SpeB in a Δsrv mutant background restores biofilm formation.

Authors:  Amity L Roberts; Robert C Holder; Sean D Reid
Journal:  BMC Res Notes       Date:  2010-11-04

9.  emm Types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: What has changed in 11 years?

Authors:  Roberta Creti; Monica Imperi; Lucilla Baldassarri; Marco Pataracchia; Simona Recchia; Giovanna Alfarone; Graziella Orefici
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

10.  Examine the characterization of biofilm formation and inhibition by targeting SrtA mechanism in Bacillus subtilis: a combined experimental and theoretical study.

Authors:  Chandrabose Selvaraj; Jeyachandran Sivakamavalli; Baskaralingam Vaseeharan; Poonam Singh; Sanjeev Kumar Singh
Journal:  J Mol Model       Date:  2014-07-20       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.